Abstracts tagged "Biomarkers"

Abstract Number: 2428 • 2016 ACR/ARHP Annual Meeting
Autoantibody Diversity in Pediatric Patients Undergoing Evaluation for Autoimmune Encephalitis: A Retrospective Investigation
Anne E Tebo¹, Thomas Haven², Aimee O. Hersh³ and Eyal Muscal⁴, ¹Pathology, University of Utah School of Medicine and ARUP Laboratories, Salt Lake City, UT, ²Department of Pathology, University of Utah, ARUP Institute of Clinical and Experimental Pathology, Salt Lake City, UT, ³Pediatrics/Rheumatology, University of Utah, Salt Lake City, UT, ⁴Immunology, allergy and Rheumatology, Baylor College of Medicine, Texas Children's Hospital, Houston, TX
Background/Purpose: Antibodies directed against N-methyl-D-aspartate type glutamate receptor (NMDAR), voltage-gated potassium channel (VGKC) or glutamic acid decarboxylase (GAD65) are frequently associated with autoimmune encephalitis (AE)…
Abstract Number: 2848 • 2016 ACR/ARHP Annual Meeting
Near Patient Anti-Nuclear Antibody Multiplex Testing Using Whole Blood for the Diagnosis of Connective Tissue Diseases in a Tertiary Care Center
Makoto Miyara¹, Jean- Luc Charuel², Sasi Mudumba³, Alice Wu³, Pascale Ghillani-Dalbin², Zahir Amoura^4,5,6, Rufus Burlingame⁷ and Lucile Musset¹, ¹Department of immunology, Pitié-Salpêtrière Hospital (AP-HP), Paris, France, ²Department of Immunology, Pitié-Salpêtrière Hospital (AP-HP), Paris, France, ³Genalyte, Inc., San Diego, CA, ⁴Internal Medecine - Centre de Référence National pour les Lupus et et le Syndrome des Antiphospholipides, Internal Medecine - Centre de Référence National pour les Lupus et et le Syndrome des Antiphospholipides, Pitié-Salpêtrière Hospital (AP-HP), Paris, France, ⁵Department of Internal Medicine 2. Referal center for SLE/APS, Pitié-Salpêtrière Hospital (AP-HP), Paris, France, ⁶Internal medicine 2, French National Reference Center for Systemic Lupus and Antiphospholipid Syndrome, Pitié-Salpêtrière Hospital (AP-HP), Paris, France, ⁷Genaltye, San Diego, CA
Background/Purpose: Detection of anti-nuclear antibodies for the diagnosis of connective tissue diseases (CTD) often requires complex algorithms to obtain conclusive results , including immunofluorescence on…
Abstract Number: 3250 • 2016 ACR/ARHP Annual Meeting
Serum MCP-1 Levels Predict Long-Term Progression of Interstitial Lung Disease in Systemic Sclerosis
Minghua Wu¹, Murray Baron², Marie Hudson³, Marvin J. Fritzler⁴, Claudia Pedroza⁵, Jun Ying¹, Gloria Salazar¹, Julio Charles⁶, Maureen D Mayes¹ and Shervin Assassi¹, ¹Department of Internal Medicine - Rheumatology, University of Texas-McGovern Medical School, Houston, TX, ²Rheumatology, McGill University, Jewish General Hospital, Montreal, QC, Canada, ³Rheumatology, Lady David Institute for Medical Research and Jewish General Hospital, Montreal, QC, Canada, ⁴Division of Rheumatology, University of Calgary, Calgary, AB, Canada, ⁵Pediatrics, University of Texas-McGovern Medical School, Houston, TX, ⁶Internal Medicine-Rheumatology, University of Texas-McGovern Medical School, Houston, TX
Background/Purpose: Currently available clinical biomarkers are not reliable predictors of long-term progression of interstitial lung disease (ILD) in the context of systemic sclerosis (SSc) A previous…
Abstract Number: 39 • 2016 ACR/ARHP Annual Meeting
Effects of Pregabalin (Lyrica®) on Cerebrospinal Fluid Substance P in Human Subjects with Fibromyalgia Syndrome
Irwin Jon Russell¹, Joel E. Michalek² and Sorleen Trevino-Mendez³, ¹Affiliated with Arthritis & Osteoporosis Center of South Texas, Medical Director, Fibromyalgia Research and Consulting, San Antonio, Texas, San Antonio, TX, ²Professor, Department of Epidemiology and Biostatistics, University of Texas Health Science Center at San Antonio, San Antonio, Texas, San Antonio, TX, ³Medical Student, Texas Tech University School of Medicine, Lubbock, TX
Background/Purpose: Fibromyalgia Syndrome [FMS] is a common chronic pain disorder. Pregabalin (PGB) is one of three medications approved by the FDA for treatment of FMS.…
Abstract Number: 647 • 2016 ACR/ARHP Annual Meeting
Genomic and Epigenetic Bioinformatics Demonstrate Dual TNF-α and IL17A Target Engagement By ABT-122, and Suggest Mainly TNF-α–Mediated Relative Target Contribution to Drug Response in MTX-IR Rheumatoid Arthritis Patients
Robert W. Georgantas III¹, Melanie Ruzek², Justin Wade Davis¹, Feng Hong¹, Elizabeth Asque¹, Kenneth Idler¹, Heikki T. Mansikka¹, Benoit Guerette¹ and Jeffrey F. Waring¹, ¹AbbVie Inc., North Chicago, IL, ²Immunology Discovery, AbbVie, Worcester, MA
Background/Purpose: ABT-122 is a dual variable domain (DVD-Ig) biologic which inhibits TNF-α and IL17A. In a 12-wk phase 2 study (NCT02141997) in MTX-IR patients (pts)…
Abstract Number: 1219 • 2016 ACR/ARHP Annual Meeting
Differential Peripheral Blood DNA Methylation Patterns Are Predictive of Radiographic OA Progression
Matlock A. Jeffries¹, Madison Andrews², Judith A. James³, Mary Beth Humphrey⁴ and Amr H. Sawalha⁵, ¹Rheumatology, University of Oklahoma Health Sciences Center, Oklahoma City, OK, ²Department of Medicine, University of Oklahoma Health Sciences Center, Oklahoma City, OK, ³Arthritis and Clinical Immunology Research Program, Oklahoma Medical Research Foundation, Oklahoma City, OK, ⁴Medicine/Rheumatology, University of Oklahoma Health Sciences Center, Oklahoma City, OK, ⁵Division of Rheumatology, University of Michigan, Ann Arbor, MI
Background/Purpose: Extensive evidence has correlated epigenetic alterations in articular tissues with both the presence and progression of human osteoarthritis, but data regarding extraarticular tissues are…
Abstract Number: 1871 • 2016 ACR/ARHP Annual Meeting
Predicting Vascular Complications in Systemic Sclerosis: A Prospective Cohort Study
Christopher A. Mecoli¹, Ami A. Shah², Francesco Boin³, Fredrick M. Wigley⁴ and Laura K. Hummers¹, ¹Johns Hopkins University School of Medicine, Baltimore, MD, ²Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD, ³Rheumatology, University California San Francisco, San Francisco, CA, ⁴Rheum Div/Mason F Lord, Johns Hopkins University School of Medicine, Baltimore, MD
Background/Purpose: Vascular disease is of fundamental importance in the pathogenesis of scleroderma. Two major vascular complications in scleroderma patients that cause substantial morbidity and mortality…
Abstract Number: 2496 • 2016 ACR/ARHP Annual Meeting
DMARD, Biologic and Small Molecule Drug Use Among ACPA Positive and ACPA Negative RA Patients in a Tertiary Referral Center
Richard Meehan¹, Eric Hoffman², David Muram³, Barbara Goldstein⁴, Jim Crooks⁵ and Pearlanne Zelarney⁶, ¹MEDICINE, National Jewish Health, Denver, CO, ²Medicine/Rheumjatology, National Jewish Health, denver, CO, ³Eli Lilly and Company, Indianapolis, IN, ⁴Rheumatology, National Jewish Health, Denver, CO, ⁵Biostatistics, National Jewish Health, Denver, CO, ⁶Bioinformatics, National Jewish Health, Denver, CO
Background/Purpose: Rheumatoid arthritis (RA) can be divided into two major subsets based on the presence or absence of antibodies to citrullinated peptide antigens (ACPA). Some…
Abstract Number: 2858 • 2016 ACR/ARHP Annual Meeting
Urinary PF4 and E-Selectin As Novel Biomarkers for Disease Activity and Renal Damage in Lupus Nephritis
Huihua Ding¹, Ling Qin¹, Samantha Stanley¹, Ramesh Saxena² and Chandra Mohan³, ¹Biomedical Engineering Department, University of Houston, Houston, TX, ²Nephrology, University of Texas Southwestern Medical Center, Dallas, TX, ³Biomedical Engineering, University of Houston, Houston, TX
Background/Purpose: Lupus nephritis (LN) is the leading cause of morbidity and mortality in systemic lupus erythematosus (SLE). The objective of this study is to validate…
Abstract Number: 63 • 2016 ACR/ARHP Annual Meeting
Identification of Immune Gene Modules in Good Responders to Adalimumab in Rheumatoid Arthritis
James OIiver¹, Darren Plant², Gisela Orozco¹, Samantha Smith¹, Kimme L. Hyrich³, Ann Morgan⁴, John Isaacs⁵, Anthony G. Wilson⁶ and Anne Barton^1,2, ¹Arthritis Research UK, Centre for Genetics and Genomics, Centre for Musculoskeletal Research, Manchester Academic Health Sciences Centre, The University of Manchester, Manchester, United Kingdom, ²NIHR Manchester Musculoskeletal BRU, Central Manchester Foundation Trust, Manchester, United Kingdom, ³Arthritis Research UK, Centre for Epidemiology, Centre for Musculoskeletal Research, Manchester Academic Health Sciences Centre, The University of Manchester, Manchester, United Kingdom, ⁴Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds and NIHR Leeds Musculoskeletal Biomedical Research Unit, Leeds Teaching Hospitals NHS Trust, Leeds, Great Britain, ⁵Institute of Cellular Medicine, Newcastle University and National Institute for Health Research Newcastle Biomedical Research Centre at Newcastle upon Tyne Hospitals NHS Foundation Trust and Newcastle University, Newcastle, United Kingdom, ⁶UCD School of Medicine and Medical Science, Conway Institute, University College Dublin, Dublin, Ireland
Background/Purpose: Despite the revolutionary impact of TNF inhibitor (TNFi) therapy in rheumatoid arthritis (RA), up to 40% of patients fail to respond adequately. Whilst non-responder…
Abstract Number: 728 • 2016 ACR/ARHP Annual Meeting
Correlation Between the Spinal MRI Findings and the Serum Level of DKK-1 in Patients with Spondyloarthritis Treated with TNF Antagonist
Zheng Zhao, Gang Wang, Yanyan Wang, Jinshui Yang, Jian Zhu and Feng Huang, Rheumatology, Chinese PLA General Hospital, Beijing, China
Background/Purpose : Recent prospective data suggest that spinal inflammatory damage in patients with ankylosing spondylitis will eventually convert into fat. In these complex inflammatory lesions,…
Abstract Number: 1247 • 2016 ACR/ARHP Annual Meeting
Diagnostic Modeling of Rheumatoid Arthritis in Oklahoma Tribal Members Using Soluble Mediators
Lucas Adams¹, Carla J. Guthridge¹, Tim Gross¹, Hua Chen¹, Krista M. Bean¹, Virginia C. Roberts¹, Julie M. Robertson², Melissa E. Munroe¹, Joel M. Guthridge³, Roger Montgomery⁴, M. Sohail Khan⁴, Fabio Mota⁵, Michael Peercy⁶, Bobby Saunkeah⁷ and Judith A. James^8,9, ¹Arthritis and Clinical Immunology, Oklahoma Medical Research Foundation, Oklahoma City, OK, ²Acelity, San Antonio, TX, ³Arthritis & Clinical Immunology, Oklahoma Medical Research Foundation, Oklahoma City, OK, ⁴Cherokee Nation Health Services, Tahlequah, OK, ⁵Chickasaw Nation Medical Center, Ada, OK, ⁶Epidemiology, Chickasaw Nation Department of Health, Ada, OK, ⁷Chickasaw Nation Department of Health, Ada, OK, ⁸Department of Medicine, University of Oklahoma Health Sciences Center, Oklahoma City, OK, ⁹Oklahoma Medical Research Foundation, Oklahoma City, OK
Background/Purpose: Diagnosis of RA is difficult in American Indian (AI) patients who often have atypical autoantibodies (e.g. ANA) with erosive arthritis. Soluble mediators may serve…
Abstract Number: 1985 • 2016 ACR/ARHP Annual Meeting
IL-18 Elevation in Macrophage Activation Syndrome: Human Evidence for a Chronic Set-Point and Murine Evidence for a Non-Hematopoietic Source
Zeshan Tariq¹, Eric Weiss², Wendy Goodspeed³, Raphaela Goldbach-Mansky⁴ and Scott Canna², ¹Autoinflammatory Pathogenesis Unit, NIAMS/NIH, Bethesd, MD, ²Autoinflammatory Pathogenesis Unit, NIAMS/NIH, Bethesda, MD, ³Office of the Clinical Director, NIAMS/NIH, Bethesda, MD, ⁴Translational Autoinflammatory Disease Studies, National Institute of Allergy and Infectious Diseases (NIAID), NIH, Bethesda, MD
Background/Purpose: Macrophage Activation Syndrome (MAS) is a life-threatening sepsis-like condition complicating many systemic JIA (sJIA) and Adult-Onset Stills Disease (AOSD) patients. We recently identified that…
Abstract Number: 2520 • 2016 ACR/ARHP Annual Meeting
Multi-Biomarker Disease Activity (MBDA) Score and Prediction of Radiographic Progression in a Randomized Study of Patients with Early RA Treated with Methotrexate Alone or with Adalimumab
Cecilie Heegaard Brahe¹, Mikkel Østergaard², Julia Sidenius Johansen³, Nadine A. Defranoux⁴, Ching Chang Hwang⁵, Xingbin Wang⁴, Rebecca J. Bolce⁴, Eric H. Sasso⁴, Kim Hørslev-Petersen⁶, Kristian Stengaard-Pedersen⁷, Lykke Midtbøll Ørnbjerg⁸, Peter Junker⁹, Torkell Ellingsen¹⁰, Palle Ahlquist¹¹, Hanne Lindegaard¹², Asta Linauskas¹³, Annette Schlemmer¹⁴, Mette Yde Dam¹⁵, Ib Tønder Hansen¹⁶, Tine Lottenburger¹¹, Christian G. Ammitzbøll¹⁷, Anette Jørgensen¹⁷, Sophine B. Krintel⁸, Johnny Lillelund Raun¹⁸ and Merete Lund Hetland^3,19, ¹Copenhagen Center for Arthritis Research, Center for Rheumatology and Spine Diseases, Rigshospitalet, Denmark, Glostrup, Denmark, ²Copenhagen Center for Arthritis Research, Center for Rheumatology and Spine Diseases, Rigshospitalet, Denmark, Copenhagen, Denmark, ³Danish Rheumatologic Biobank and DANBIO registry, Rigshospitalet, Glostrup, Gentofte and Herlev University Hospital, Copenhagen, Denmark, ⁴Crescendo Bioscience Inc., South San Francisco, CA, ⁵Biostatistics, Crescendo Bioscience Inc., South San Francisco, CA, ⁶King Christian X Hospital for Rheumatic Diseases, Graasten, Denmark, ⁷Rigshospitalet (Glostrup and Blegdamsvej), Århus University Hospital, Odense University Hospital, Herlev/Gentofte Hospital, Slagelse Sygehus, Chr X hospital (University of South Denmark) and Zitelab Aps, DANBIO Registry and Departments of Rheumatology, Copenhagen, Denmark, ⁸Copenhagen Center for Arthritis Research, Center for Rheumatology and Spine Diseases, Rigshospitalet, Copenhagen, Denmark, ⁹Department of Rheumatology C, Odense University Hospital, Odense, Denmark, ¹⁰Department of Rheumatology, Odense University Hospital, Odense, DK, Odense, Denmark, ¹¹Department of Medicine, Vejle Regional Hospital, Vejle, Denmark, ¹²The DANBIO registry and the Danish Departments of Rheumatology, Odense, Denmark, ¹³The DANBIO registry and the Danish Departments of Rheumatology, Copenhagen, Denmark, ¹⁴9Department of Rheumatology, Aalborg University Hospital, Aalborg, Denmark, ¹⁵Diagnostic Centre, Silkeborg Regional Hospital, Silkeborg, Denmark, ¹⁶Department of Rheumatology, Aarhus University Hospital, Aarhus, Denmark, ¹⁷Department of Rheumatology, Institute of Clinical Medicine, Aarhus University Hospital, Aarhus, Denmark, ¹⁸King Christian X Hospital for Rheumatic Diseases, South Jutland Hospital, Graasten, Denmark, ¹⁹Copenhagen Center for Arthritis Research, Center for Rheumatology and Spine Diseases, Rigshospitalet, Denmark,, Copenhagen, Denmark
Background/Purpose: The multi-biomarker disease activity (MBDA) score, which combines 12 serum biomarkers to measure RA disease activity on a scale of 1−100, has been found…
Abstract Number: 2871 • 2016 ACR/ARHP Annual Meeting
Unaffected Lupus Relatives Are Distinguished from SLE Patients and Unaffected Individuals Not Related to SLE Patients By Lupus-Specific Connective Tissue Disease Questionnaire Scores, Autoantibodies, and Distinct Soluble Mediators
Melissa E. Munroe¹, Kendra A. Young², Jill M. Norris², Teresa Aberle¹, Virginia C. Roberts¹, Joel M. Guthridge³, Diane L. Kamen⁴, Gary S. Gilkeson⁵, Michael Weisman⁶, Mariko Ishimori⁶, Daniel J Wallace⁷, David Karp⁸, Kathy L. Sivils¹, John B. Harley^9,10 and Judith A. James^11,12, ¹Arthritis and Clinical Immunology, Oklahoma Medical Research Foundation, Oklahoma City, OK, ²Epidemiology, Colorado School of Public Health, Aurora, CO, ³Arthritis & Clinical Immunology, Oklahoma Medical Research Foundation, Oklahoma City, OK, ⁴Medicine/Rheumatology & Immunology, Medical University of South Carolina, Charleston, SC, ⁵Department of Medicine, Division of Rheumatology, Medical University of South Carolina, Charleston, SC, ⁶Rheumatology, Cedars-Sinai Medical Center, Los Angeles, CA, ⁷Division of Rheumatology, Cedars-Sinai Medical Center, Los Angeles, CA, ⁸Internal Medicine/Division of Rheumatic Diseases, University of Texas Southwestern Medical Center, Dallas, TX, ⁹US Department of Veterans Affairs Medical Center, Cincinnati, OH, ¹⁰Center for Autoimmune Genomics and Etiology (CAGE), Cincinnati Childrens Hospital, Cincinnati, OH, ¹¹Arthritis and Clinical Immunology Research Program, Oklahoma Medical Research Foundation, Oklahoma City, OK, ¹²Department of Medicine, University of Oklahoma Health Sciences Center, Oklahoma City, OK
Background/Purpose: Identifying populations at risk of SLE is essential to curtail inflammatory damage and select individuals for prevention trials. Blood relatives (Rel) of lupus patients…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].